AAAAAA

   
Results: 1-10 |
Results: 10
PILOT-STUDY OF NIMORAZOLE AS A HYPOXIC-CELL SENSITIZER WITH THE CHARTREGIMEN IN HEAD AND NECK-CANCER
Authors: COTTRILL CP BISHOP K WALTON MI HENK JM
Citation: Cp. Cottrill et al., PILOT-STUDY OF NIMORAZOLE AS A HYPOXIC-CELL SENSITIZER WITH THE CHARTREGIMEN IN HEAD AND NECK-CANCER, International journal of radiation oncology, biology, physics, 42(4), 1998, pp. 807-810
CHARACTERIZATION OF THE P53 STATUS, BCL-2 EXPRESSION AND RADIATION AND PLATINUM DRUG-SENSITIVITY OF A PANEL OF HUMAN OVARIAN-CANCER CELL-LINES
Authors: PESTELL KE MEDLOW CJ TITLEY JC KELLAND LR WALTON MI
Citation: Ke. Pestell et al., CHARACTERIZATION OF THE P53 STATUS, BCL-2 EXPRESSION AND RADIATION AND PLATINUM DRUG-SENSITIVITY OF A PANEL OF HUMAN OVARIAN-CANCER CELL-LINES, International journal of cancer, 77(6), 1998, pp. 913-918
THE RENAL EFFECTS OF THE WATER-SOLUBLE, NON-FOLYLPOLYGLUTAMATE SYNTHETASE DEPENDENT THYMIDYLATE SYNTHASE INHIBITOR ZD9331 IN MICE
Authors: WALTON MI MITCHELL F AHERNE GW MEDLOW CJ BOYLE FT JACKSON AL
Citation: Mi. Walton et al., THE RENAL EFFECTS OF THE WATER-SOLUBLE, NON-FOLYLPOLYGLUTAMATE SYNTHETASE DEPENDENT THYMIDYLATE SYNTHASE INHIBITOR ZD9331 IN MICE, British Journal of Cancer, 78(11), 1998, pp. 1457-1463
ROLE OF P53 IN HUMAN OVARIAN-CANCER TUMOR XENOGRAFTS CURABLE WITH CISPLATIN
Authors: PESTELL KE MEDLOW CJ JONES M VALENTI M BRUNTON L KELLAND LR WALTON MI
Citation: Ke. Pestell et al., ROLE OF P53 IN HUMAN OVARIAN-CANCER TUMOR XENOGRAFTS CURABLE WITH CISPLATIN, British Journal of Cancer, 78, 1998, pp. 14-14
THE ROLE OF FUNCTIONAL P53 IN CISPLATIN CHEMOSENSITIVITY IN A PANEL OF HUMAN OVARIAN-CANCER CELL-LINES
Authors: WALTON MI KOSHY P MEDLOW CJ SHARP S KELLAND LR SHARP S TITLEY J
Citation: Mi. Walton et al., THE ROLE OF FUNCTIONAL P53 IN CISPLATIN CHEMOSENSITIVITY IN A PANEL OF HUMAN OVARIAN-CANCER CELL-LINES, British Journal of Cancer, 78, 1998, pp. 69-69
PRECLINICAL PHARMACOLOGY AND ANTITUMOR-ACTIVITY OF THE NOVEL SEQUENCESELECTIVE DNA MINOR-GROOVE CROSS-LINKING AGENT DSB-120
Authors: WALTON MI GODDARD P KELLAND LR THURSTON DE HARRAP KR
Citation: Mi. Walton et al., PRECLINICAL PHARMACOLOGY AND ANTITUMOR-ACTIVITY OF THE NOVEL SEQUENCESELECTIVE DNA MINOR-GROOVE CROSS-LINKING AGENT DSB-120, Cancer chemotherapy and pharmacology, 38(5), 1996, pp. 431-438
PRECLINICAL PHARMACOLOGY OF CB30900, A NOVEL DIPEPTIDE INHIBITOR OF THYMIDYLATE SYNTHASE, IN MICE
Authors: WALTON MI GIBSON W AHERNE GW LAWRENCE N STEPHENS TC SMITH MN JACKMAN AL
Citation: Mi. Walton et al., PRECLINICAL PHARMACOLOGY OF CB30900, A NOVEL DIPEPTIDE INHIBITOR OF THYMIDYLATE SYNTHASE, IN MICE, The Journal of pharmacology and experimental therapeutics, 277(2), 1996, pp. 909-916
PRECLINICAL PHARMACOLOGY OF 1069C85, A NOVEL TUBULIN BINDER
Authors: RAYNAUD FI KELLAND LR WALTON MI JUDSON IR
Citation: Fi. Raynaud et al., PRECLINICAL PHARMACOLOGY OF 1069C85, A NOVEL TUBULIN BINDER, Cancer chemotherapy and pharmacology, 35(2), 1994, pp. 169-173
PHARMACOKINETICS AND BIOREDUCTIVE METABOLISM OF THE NOVEL BENZOTRIAZINE DI-N-OXIDE HYPOXIC CELL CYTOTOXIN TIRAPAZAMINE (WIN-59075 - SR-4233- NSC-130181) IN MICE
Authors: WALTON MI WORKMAN P
Citation: Mi. Walton et P. Workman, PHARMACOKINETICS AND BIOREDUCTIVE METABOLISM OF THE NOVEL BENZOTRIAZINE DI-N-OXIDE HYPOXIC CELL CYTOTOXIN TIRAPAZAMINE (WIN-59075 - SR-4233- NSC-130181) IN MICE, The Journal of pharmacology and experimental therapeutics, 265(2), 1993, pp. 938-947
CONSTITUTIVE EXPRESSION OF HUMAN BCL-2 MODULATES NITROGEN-MUSTARD ANDCAMPTOTHECIN INDUCED APOPTOSIS
Authors: WALTON MI WHYSONG D OCONNOR PM HOCKENBERY D KORSMEYER SJ KOHN KW
Citation: Mi. Walton et al., CONSTITUTIVE EXPRESSION OF HUMAN BCL-2 MODULATES NITROGEN-MUSTARD ANDCAMPTOTHECIN INDUCED APOPTOSIS, Cancer research, 53(8), 1993, pp. 1853-1861
Risultati: 1-10 |